178 related articles for article (PubMed ID: 24859833)
21. Predictive value of ERCC1 single-nucleotide polymorphism in patients receiving platinum-based chemotherapy for locally-advanced and advanced non-small cell lung cancer--a pilot study.
Krawczyk P; Wojas-Krawczyk K; Mlak R; Kucharczyk T; Biernacka B; Milanowski J
Folia Histochem Cytobiol; 2012 Apr; 50(1):80-6. PubMed ID: 22532140
[TBL] [Abstract][Full Text] [Related]
22. [Association between polymorphisms of ERCC1 and response in patients with advanced non-small cell lung cancer receiving cisplatin-based chemotherapy].
Wang J; Zhang Q; Zhang H; Wang Q; Yang X; Gu Y; Zhang S
Zhongguo Fei Ai Za Zhi; 2010 Apr; 13(4):337-41. PubMed ID: 20677561
[TBL] [Abstract][Full Text] [Related]
23. A C118T polymorphism of ERCC1 and response to cisplatin chemotherapy in patients with late-stage non-small cell lung cancer.
Cheng J; Ha M; Wang Y; Sun J; Chen J; Wang Y; Tong C
J Cancer Res Clin Oncol; 2012 Feb; 138(2):231-8. PubMed ID: 22102173
[TBL] [Abstract][Full Text] [Related]
24. Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients.
Krawczyk P; Kucharczyk T; Kowalski DM; Powrózek T; Ramlau R; Kalinka-Warzocha E; Winiarczyk K; Knetki-Wróblewska M; Wojas-Krawczyk K; Kałakucka K; Dyszkiewicz W; Krzakowski M; Milanowski J
J Cancer Res Clin Oncol; 2014 Dec; 140(12):2047-57. PubMed ID: 25028118
[TBL] [Abstract][Full Text] [Related]
25. Role of DNA repair gene polymorphisms in the efficiency of platinum-based adjuvant chemotherapy for non-small cell lung cancer.
Mathiaux J; Le Morvan V; Pulido M; Jougon J; Bégueret H; Robert J
Mol Diagn Ther; 2011 Jun; 15(3):159-66. PubMed ID: 21766907
[TBL] [Abstract][Full Text] [Related]
26. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer.
Kalikaki A; Kanaki M; Vassalou H; Souglakos J; Voutsina A; Georgoulias V; Mavroudis D
Clin Lung Cancer; 2009 Mar; 10(2):118-23. PubMed ID: 19362955
[TBL] [Abstract][Full Text] [Related]
27. Genetic polymorphisms in nucleotide excision repair pathway influences response to chemotherapy and overall survival in osteosarcoma.
Sun Y; Wu Y; Li W; Kong Z; Zou X
Int J Clin Exp Pathol; 2015; 8(7):7905-12. PubMed ID: 26339355
[TBL] [Abstract][Full Text] [Related]
28. Genetic variability of ERCC1 genes in NER pathway influences the treatment outcome of gastric cancer.
Bai Y; Wang L; Li G; Fang X; Li Y; Yang S
Int J Clin Exp Pathol; 2015; 8(10):13367-73. PubMed ID: 26722542
[TBL] [Abstract][Full Text] [Related]
29. Predictive value of ERCC1 and RRM1 gene single-nucleotide polymorphisms for first-line platinum- and gemcitabine-based chemotherapy in non-small cell lung cancer patients.
Mlak R; Krawczyk P; Ramlau R; Kalinka-Warzocha E; Wasylecka-Morawiec M; Wojas-Krawczyk K; Kucharczyk T; Homa I; Kozioł P; Ciesielka M; Chudziak D; Milanowski J
Oncol Rep; 2013 Nov; 30(5):2385-98. PubMed ID: 23982437
[TBL] [Abstract][Full Text] [Related]
30. Study on the ERCC1 gene polymorphism response to chemotherapy and prognosis of gastric cancer.
Liu L; Li CH; Jin TF; Xu DY
Genet Mol Res; 2014 Oct; 13(4):8722-8. PubMed ID: 25366763
[TBL] [Abstract][Full Text] [Related]
31. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
Li Z; Qing Y; Guan W; Li M; Peng Y; Zhang S; Xiong Y; Wang D
Cancer Chemother Pharmacol; 2014 Oct; 74(4):777-86. PubMed ID: 25107571
[TBL] [Abstract][Full Text] [Related]
32. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.
Li F; Sun X; Sun N; Qin S; Cheng H; Feng J; Chen B; Cheng L; Lu Z; Ji J; Zhou Y
Am J Clin Oncol; 2010 Oct; 33(5):489-94. PubMed ID: 20351547
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of EGFR mutation and ERCC1 in patients with non-small cell lung cancer undergoing platinum-based chemotherapy.
Yamashita F; Azuma K; Yoshida T; Yamada K; Kawahara A; Hattori S; Takeoka H; Zaizen Y; Kawayama T; Kage M; Hoshino T
PLoS One; 2013; 8(8):e71356. PubMed ID: 23940741
[TBL] [Abstract][Full Text] [Related]
34. A meta-analytic review of ERCC1/MDR1 polymorphism and chemosensitivity to platinum in patients with advanced non-small cell lung cancer.
Wei HB; Hu J; Shang LH; Zhang YY; Lu FF; Wei M; Yu Y
Chin Med J (Engl); 2012 Aug; 125(16):2902-7. PubMed ID: 22932088
[TBL] [Abstract][Full Text] [Related]
35. XPG polymorphisms are associated with prognosis of advanced non-small cell lung cancer treated with platinum-based doublet chemotherapy.
Zou HZ; Zhao YQ
Genet Mol Res; 2015 Jan; 14(1):500-6. PubMed ID: 25729984
[TBL] [Abstract][Full Text] [Related]
36. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer.
Isla D; Sarries C; Rosell R; Alonso G; Domine M; Taron M; Lopez-Vivanco G; Camps C; Botia M; Nuñez L; Sanchez-Ronco M; Sanchez JJ; Lopez-Brea M; Barneto I; Paredes A; Medina B; Artal A; Lianes P
Ann Oncol; 2004 Aug; 15(8):1194-203. PubMed ID: 15277258
[TBL] [Abstract][Full Text] [Related]
37. The role of expression and polymorphism of the BAG-1 gene in response to platinum-based chemotherapeutics in NSCLC.
Wang YD; Ha MW; Cheng J; Zhang WL; Cong X; Tong CY; Sun J
Oncol Rep; 2012 Apr; 27(4):979-86. PubMed ID: 22179630
[TBL] [Abstract][Full Text] [Related]
38. Pharmacogenetic role of ERCC1 genetic variants in treatment response of platinum-based chemotherapy among advanced non-small cell lung cancer patients.
Yu D; Shi J; Sun T; Du X; Liu L; Zhang X; Lu C; Tang X; Li M; Xiao L; Zhang Z; Yuan Q; Yang M
Tumour Biol; 2012 Jun; 33(3):877-84. PubMed ID: 22249976
[TBL] [Abstract][Full Text] [Related]
39. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy.
Ryu JS; Hong YC; Han HS; Lee JE; Kim S; Park YM; Kim YC; Hwang TS
Lung Cancer; 2004 Jun; 44(3):311-6. PubMed ID: 15140544
[TBL] [Abstract][Full Text] [Related]
40. Genetic variability of DNA repair mechanisms influences chemotherapy outcome of gastric cancer.
Yu H; Wu X; Zhang Y; Jin Z; Li G; Zhao H
Int J Clin Exp Pathol; 2015; 8(4):4106-12. PubMed ID: 26097599
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]